• Molecular NameTranexamic_acid
  • SynonymTranexamsaeure; tranexmic acid; Tranhexamic acid; Trans AMCHA; trans-4-aminomethylcyclohexane-1-carboxylic acid; trans-Amcha; trans-Tranexamic acid
  • Weight157.213
  • Drugbank_IDDB00302
  • ACS_NO1197-18-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-1.68
  • pkaN/A
  • LogD (pH=7, predicted)-4.18
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.13
  • LogSw (predicted, AB/LogsW2.0)53.82
  • Sw (mg/ml) (predicted, ACD/Labs)115.8
  • No.of HBond Donors3
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds2
  • TPSA63.32
  • StatusFDA approved
  • AdministrationInjection and oral
  • PharmacologyAn antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin.
  • Absorption_value55.0
  • Absorption (description)Absorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
  • Caco_2N/A
  • Bioavailability34.0
  • Protein binding3.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmOnly a small fraction of the drug is metabolized (less than 5%).
  • Half life3.1 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A